| Nucleic sequences encoding an at2 receptor-interacting protein (atip) and their applications -> Monitor Keywords |
|
|
  Nucleic sequences encoding an at2 receptor-interacting protein (atip) and their applicationsUSPTO Application #: 20060040277Title: Nucleic sequences encoding an at2 receptor-interacting protein (atip) and their applications Abstract: The invention concerns nucleic sequences coding for a protein capable of interacting with the AT2 receptor, oligonucleotides included in said sequences, their application as probes and for expressing said proteins, vectors useful for said expression, host cells containing said vectors, and study model of AT2 receptor. The invention also concerns said proteins and their uses. Said isolated nucleic acid fragment coding for a protein capable of binding with the AT2 receptor is selected among the group consisting of the sequences SEQ ID NO: 1, 3, 5, 7 and 9. (end of abstract)
Agent: Alston & Bird LLP Bank Of America Plaza - Charlotte, NC, US Inventors: Nathalie Elbaz, Clara Nahmias, Donny Strosberg Arthur USPTO Applicaton #: 20060040277 - Class: 435006000 (USPTO) Related Patent Categories: Chemistry: Molecular Biology And Microbiology, Measuring Or Testing Process Involving Enzymes Or Micro-organisms; Composition Or Test Strip Therefore; Processes Of Forming Such Composition Or Test Strip, Involving Nucleic Acid The Patent Description & Claims data below is from USPTO Patent Application 20060040277. Brief Patent Description - Full Patent Description - Patent Application Claims
[0001] The present invention relates to nucleic sequences encoding a protein capable of interacting with the AT2 receptor, to oligonucleotides contained in the said sequences, to their applications as probes and for the expression of the said proteins, to the vectors useful for the said expression, to the host cells containing the said vectors and to a model for studying the AT2 receptor. [0002] The present invention also relates to the said proteins and to their applications. [0003] The octapeptide, angiotensin II, mainly known as a regulator of blood pressure, has also been described as an important modulator of cell growth. Interestingly, this peptide appears to exert opposite effects on cell growth according to whether it is bound to one or the other of its two subtypes of membrane receptors (AT1 or AT2). [0004] The AT2 receptor subtype, which also belongs to the G protein-coupled receptor family, is still poorly characterized both from the point of view of its mechanisms of activation and its physiological role (C. Nahmias et al., Trends Pharmacol Sci, 1995, 16, 223-225). Several arguments suggest, however, a role for this receptor in the phenomena of cell proliferation, differentiation or adhesion. [0005] The AT2 receptor is highly expressed during foetal life, disappears in adults in most tissues, but becomes reexpressed under pathophysiological conditions involving restructuring of the tissues. [0006] Studies carried out in vivo have demonstrated the inhibitory role exerted by the AT2 subtype on the proliferation of the muscle cells of the tunica intima vasorum after vascular lesion (P. Janiak et al., Hypertension, 1992, 20, 737-745; M Nakajima et al., Proc. Natl. Acad. Sci. USA, 1995, 92, 10663-10667). [0007] Moreover, the stimulation of the AT2 receptor activates phosphatase SHP-1 (Bedecs K., et al; Biochem. J., 1997, 325, 449-454). The fact that the AT2 receptor activates a phosphatase is consistent with its antiproliferative effects. [0008] In the light of the above, it has been shown that, on cells in culture, the AT2 receptor: [0009] inhibits the synthesis of DNA and proliferation, which are induced by angiotensin II (Ang II) and bFGF (M. Stoll et al., J. Clin. Invest., 1995, 95, 651-657), [0010] induces apoptosis (T. Yamada et al., Proc. Natl. Acad. Sci. USA, 1996, 93, 156-160), and [0011] induces neuronal differentiation (L. Laflamme et al., J. Biol. Chem., 1996, 271, 22729-22735). [0012] Studies of the signalling pathways associated with the AT2 receptor have been undertaken in cells of the N1E-115 line which are derived from a murine neuroblastoma and which express only the AT2 subtype. A first study has made it possible to demonstrate rapid and transient dephosphorylation of some proteins on the tyrosine residues following the treatment of N1E-115 cells with angiotensin II (C. Nahmias et al., Biochem. J., 1995, 306, 87-92). It has also been shown that the AT2 receptor interferes with the pathways for activation of growth factor receptors and inhibits the activity of MAP kinases (ERK1 and ERK2) (mitogen-activated protein), which play a key role in the phenomena of cell proliferation and differentiation. The inhibitory effect of AT2 on the activation of MAP kinases is rapid and transient, does not involve a regulatory protein sensitive to the pertussis toxin (of the Gi/Go type), but involves the activation of an orthovanadate-sensitive tyrosine phosphatase. [0013] Taking into account the role of the AT2 receptor in cell proliferation, the inventors have sought to develop tools capable of regulating the action of the AT2 receptor. Indeed, the activation of the AT2 receptor may have repercussions in cancerology (inhibition of cell proliferation). [0014] In general, the AT2 receptor has opposite effects to those of AT1 on the activation of MAP kinases and on cell proliferation; study of the communication which may exist between these two receptor subtypes, which bind the same ligand, is consequently of interest. [0015] The study of the signalling pathways and of the regulation of the AT2 receptor also represents a major stake for human health knowing that antagonists of the AT1 receptor are currently administered to patients with hypertension. In this context, it is essential to know the biological effects associated with the AT2 receptor which remains activable by circulating Ang II in this type of treatment. [0016] The subject of the present invention is an isolated nucleic acid (DNA or RNA) fragment, encoding a protein capable of binding to the AT2 receptor, which fragment is selected from the group consisting of the sequences SEQ ID NO:1, 3, 5, 7 and 9, as represented in the sequence listing included in the present application. [0017] These various sequences correspond to the complementary DNA (cDNA) encoding all or part of the protein called hereinafter ATIP (AT2 interacting protein). [0018] The sequence SEQ ID NO:1 (1803 bp) corresponds to the complete nucleic sequence of mouse ATIP and includes both the parts encoding the AT2 receptor binding protein and the noncoding parts. [0019] The sequence NO:3 (1323 bp) corresponds to the nucleic acid sequence of the coding part of the sequence SEQ ID NO:1, while the sequence SEQ ID NO:5 corresponds to the sequence NO:1 fragment obtained by the two-hybrid technique (A Plessis et al., M/S, 1994, 9, I-1K; J. Luban et al., Curr. Op. Biotechnol., 1995, 6, 59-64). [0020] The sequence SEQ ID NO:7 (3742 bp) corresponds to the complete nucleic sequence of the human cDNA and includes both the parts encoding the protein homologous to the mouse ATIP and the noncoding parts. [0021] The sequence SEQ ID NO:9 (1308 bp) corresponds to the coding part of the sequence SEQ ID NO:7. [0022] The subject of the present invention is also transcripts, characterized in that they are complementary to the sequences in accordance with the invention and are in particular generated from the said sequences. [0023] The subject of the present invention is, in addition, fragments of the said sequences comprising between 20 and 400 bp, useful as probes or as primers, for the detection of the sequences SEQ ID NO:1, 3, 5, 7 or 9, or of homologous sequences. [0024] Among the said fragments, there may be mentioned in particular a probe of 354 bp (SEQ ID NO:5) as well as any fragment of 20 bp to 400 bp included in the sequences SEQ ID NO:1, 3, 5, 7 or 9. [0025] As primer, there will be used in particular the sequence SEQ ID NO:10 (antisense oligonucleotide) which makes it possible in particular to amplify the 5' parts of the various mRNAs corresponding to ATIP (5' RACE technique: Marathon cDNA amplification kit, Clontech). [0026] It is also possible to use, as amplification primers, any pair of oligonucleotides of more than 20 bp and comprising part of the ATIP (human or mouse) nucleic sequence, in particular the pair SEQ ID NO:11-SEQ ID NO:12. [0027] The preferred hybridization (prehybridization and hybridization) conditions are in particular the following: 45% formamide, 9% dextran sulphate, 0.2% BSA, 0.2% polyvinyl pyrrolidone, 0.2% Ficoll, 0.1% sodium pyrophosphate, 0.01% SDS, 0.05 mM Tris pH 7.5, 0.9 M NaCl and rinses to a stringency corresponding to the buffer: 1.times.SSC, 0.1% SDS. Continue reading... Full patent description for Nucleic sequences encoding an at2 receptor-interacting protein (atip) and their applications Brief Patent Description - Full Patent Description - Patent Application Claims Click on the above for other options relating to this Nucleic sequences encoding an at2 receptor-interacting protein (atip) and their applications patent application. ###  How KEYWORD MONITOR works... a FREE service from FreshPatents1. Sign up (takes 30 seconds). 2. Fill in the keywords to be monitored. 3. Each week you receive an email with patent applications related to your keywords. Start now! - Receive info on patent apps like Nucleic sequences encoding an at2 receptor-interacting protein (atip) and their applications or other areas of interest. ### Previous Patent Application: Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of ovarian cancer Next Patent Application: Nucleotide sequences specific to francisella tularensis and methods for the detection of francisella tularensis Industry Class: Chemistry: molecular biology and microbiology ### FreshPatents.com Support Thank you for viewing the Nucleic sequences encoding an at2 receptor-interacting protein (atip) and their applications patent info. IP-related news and info Results in 4.21086 seconds Other interesting Feshpatents.com categories: Accenture , Agouron Pharmaceuticals , Amgen , AT&T , Bausch & Lomb , Callaway Golf |
||
